Is Bimzelx in Shortage in 2026?

If you've been trying to get Bimzelx (Bimekizumab-bkzx) and running into walls, you might be wondering if there's a formal shortage. The short answer: no, Bimzelx is not on the FDA's official drug shortage list as of early 2026. But that doesn't mean it's easy to get.

The difficulty in accessing Bimzelx comes from its specialty pharmacy distribution model, insurance requirements, and high cost — not a manufacturing problem. In this post, we'll break down the current situation and what you can do about it.

Why Is Bimzelx Hard to Find If There's No Shortage?

Even without a formal shortage, several factors make Bimzelx feel scarce:

Specialty Pharmacy Distribution

Bimzelx is a biologic that must be stored at refrigerated temperatures (36°F to 46°F). It's only available through specialty pharmacies — not your local drugstore. This limits where and how you can pick it up.

Insurance Gatekeeping

Virtually all insurance plans require prior authorization before covering Bimzelx. Many also require step therapy, meaning you must try and fail other biologics first. This process can take weeks, leaving patients without medication in the meantime.

Expanding Indications Mean Growing Demand

When Bimzelx first launched in the U.S. in late 2023, it was approved only for plaque psoriasis. Since then, the FDA has added approvals for psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. More patients qualifying for Bimzelx means more demand on the specialty pharmacy supply chain.

For a deeper explanation, read why Bimzelx is so hard to find in 2026.

How Much Does Bimzelx Cost in 2026?

Cost remains one of the biggest barriers to accessing Bimzelx. Here's what you can expect:

• Cash price (no insurance): $16,000 to $22,000 per month
• With commercial insurance + UCB savings card: As low as $5 per dose
• With insurance but no savings card: Copays can range from hundreds to thousands of dollars depending on your plan
• Medicare/Medicaid: Coverage varies; the UCB copay card is not available for government insurance plans, but the Patient Assistance Program may help

For detailed savings strategies, see how to save money on Bimzelx in 2026.

New Options and Developments in 2026

The landscape for treating psoriasis, PsA, and HS continues to evolve:

• Bimzelx's HS approval (November 2024) made it the first IL-17A/F inhibitor approved for hidradenitis suppurativa, opening a new treatment option for HS patients
• Growing specialty pharmacy networks — more pharmacies are adding Bimzelx to their formularies as demand increases
• Insurance policies are evolving — some plans are beginning to cover Bimzelx with fewer step therapy requirements as clinical evidence mounts

How to Find Bimzelx in Stock

Here are practical steps to get your prescription filled:

1. Search on Medfinder — check real-time specialty pharmacy availability
2. Enroll in UCB MyNavigate — get a Nurse Navigator to help with insurance and pharmacy coordination, plus potential copay of just $5 per dose
3. Ask your doctor to submit prior authorization early — don't wait for the pharmacy to initiate it
4. Follow up on insurance decisions within 48-72 hours — persistence pays off
5. Appeal any denials — many are overturned with additional documentation from your doctor

For more tips, read our guide on how to find Bimzelx in stock near you.

What If You Can't Wait?

If your condition is flaring and you need treatment now, talk to your doctor about alternatives to Bimzelx. Options include:

• Cosentyx (Secukinumab) — IL-17A inhibitor, similar mechanism
• Taltz (Ixekizumab) — another IL-17A inhibitor
• Humira (Adalimumab) — TNF inhibitor with wide availability and biosimilar options
• Stelara (Ustekinumab) — IL-12/23 inhibitor, less frequent dosing

These can serve as bridge therapy while you continue working on getting Bimzelx.

Final Thoughts

While there's no official Bimzelx shortage in 2026, the practical reality is that many patients face significant delays in getting this medication. The barriers are insurance-related and distribution-related, not manufacturing-related.

Stay proactive: use Medfinder to track availability, enroll in savings programs, and work closely with your healthcare team. Your treatment shouldn't stall because of paperwork.